Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease. Read More
Tissue-plasminogen activator (tPA, sold as Activase by Roche AG) is the only stroke treatment that has made it to the market at all, amidst a bevy of failed attempts to develop additional stroke drugs. But its limitations are twofold. Read More
• Novelos Pharmaceuticals Inc., of Madison, Wisc., filed an S-1 with the SEC seeking to raise $4 million through an offering of 4 million shares. Read More
• Angion Biomedica Corp., of Uniondale, N.Y., said the first patient was dosed in a Phase II trial testing BB3, a small-molecule mimetic of hepatocyte growth factor, for the treatment of heart attack. Read More
• Sanofi SA, of Paris, and Brigham and Women's Hospital, of Boston, began a new research collaboration to develop an immunomodulatory therapy for Type I diabetes. Read More
• Hemispherx Biopharma Inc., of Philadelphia, said it submitted a new drug application for Ampligen for the treatment of chronic fatigue syndrome to regulatory authorities in Argentina, under its orphan drug regulations. GP Pharm SA, of Gava, Spain, is Hemispherx's partner in Argentina and is responsible for commercialization of Ampligen and Alferon N Injection, which gained regulatory approval in Argentina earlier this year for the treatment of genital warts. Read More
• GlaxoSmithKline plc, of London, said it began a Phase III trial of its herpes zoster vaccine candidate for the prevention of shingles in immunocompromised patients. Read More
